Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-490 in Relapsed/Refractory Multiple Myeloma
NCT05719701Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of ICP-490 in multiple myeloma (MM), sponsored by InnoCare Pharma. Started Mar 2023; status: recruiting.
02
Drugs
ICP-490
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05719701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719701.